Goat Anti-Rabbit IgG Fc (DyLight® 488) (ab96983)
Key features and details
- Goat Anti-Rabbit IgG Fc (DyLight® 488)
- Conjugation: DyLight® 488. Ex: 493nm, Em: 518nm
- Host species: Goat
- Isotype: IgG
- Suitable for: Flow Cyt, ICC/IF, IHC-P
Overview
-
Product name
Goat Anti-Rabbit IgG Fc (DyLight® 488)
See all IgG secondary antibodies -
Host species
Goat -
Target species
Rabbit -
Specificity
By immunoelectrophoresis and ELISA this antibody reacts specifically with Rabbit IgG. -
Tested applications
Suitable for: Flow Cyt, ICC/IF, IHC-Pmore details -
Immunogen
Other Immunogen Type corresponding to Rabbit IgG.
-
Conjugation
DyLight® 488. Ex: 493nm, Em: 518nm
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 6.8
Preservative: 0.09% Sodium azide
Constituents: 0.2% BSA, PBS -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
Antiserum was solid phase adsorbed to ensure class specificity. This antibody was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to DyLight® 488. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab96983 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
1/50 - 1/200.
|
|
ICC/IF |
1/50 - 1/500.
|
|
IHC-P |
1/50 - 1/500.
|
Notes |
---|
Flow Cyt
1/50 - 1/200. |
ICC/IF
1/50 - 1/500. |
IHC-P
1/50 - 1/500. |
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (1)
ab96983 has been referenced in 1 publication.
- Ye J et al. miR-4666-3p and miR-329 Synergistically Suppress the Stemness of Colorectal Cancer Cells via Targeting TGF-ß/Smad Pathway. Front Oncol 9:1251 (2019). PubMed: 31824844